OSI Pharmaceuticals to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16, 2009
11 March 2009 - 1:00AM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that
Mr. Pierre Legault, Executive Vice President & Chief Financial
Officer of OSI Pharmaceuticals, will present at the Cowen
Healthcare Conference in Boston, MA on Monday, March 16, 2009 at
2:25p.m. (Eastern Time). Mr. Legault will provide an overview on
the Company�s product portfolio and business developments.
The presentation will be webcast live and may be accessed by
visiting OSI�s website at www.osip.com. A replay of the webcast
will also be available on the Company�s website until March 30,
2009.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality and novel pharmaceutical products designed to extend
life and/or improve the quality of life for patients with cancer
and diabetes/obesity. The Company�s oncology programs are focused
on developing molecular targeted therapies designed to change the
paradigm of cancer care. OSI�s diabetes/obesity efforts are
committed to the generation of novel, targeted therapies for the
treatment of type 2 diabetes and obesity. OSI's flagship product,
Tarceva� (erlotinib), is the first drug discovered and developed by
OSI to obtain FDA approval and the only EGFR inhibitor to have
demonstrated the ability to improve survival in both non-small cell
lung cancer and pancreatic cancer patients in certain settings. OSI
markets Tarceva through partnerships with Genentech, Inc. in the
United States and with Roche throughout the rest of the world. For
additional information about OSI, please visit .
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, the completion of clinical
trials, the FDA review process and other governmental regulation,
OSI's and its collaborators' abilities to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, the ability to effectively market
products, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles